The Alport Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Alport Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Alport Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Alport Syndrome and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Alport Syndrome by 15 companies/universities/institutes. The top development phase for Alport Syndrome is phase ii with five drugs in that stage. The Alport Syndrome pipeline has 15 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Alport Syndrome pipeline products market are: Calliditas Therapeutics, Chinook Therapeutics and Travere Therapeutics.
The key targets in the Alport Syndrome pipeline products market include Endothelin 1 Receptor (Endothelin A Receptor or EDNRA), Dystrophin (DMD), and Free Radical.
The key mechanisms of action in the Alport Syndrome pipeline product include Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Antagonist with two drugs in Phase II. The Alport Syndrome pipeline products include five routes of administration with the top ROA being Oral and three key molecule types in the Alport Syndrome pipeline products market including Small Molecule, and Monoclonal Antibody.
Alport Syndrome overview
Alport syndrome is a genetic disorder characterized by glomerulonephritis, end-stage kidney disease, and hearing loss. It is caused by an inherited defect in type IV collagen—a structural material that is needed for the normal function of different parts of the body. Since type IV collagen is found in the ears, eyes, and kidneys, this explains why Alport syndrome affects different seemingly unrelated parts of the body. Alport syndrome is inherited in an X-linked manner and is caused by genetic changes in the COL4A5 gene. In the remaining cases, it may be inherited in either an autosomal recessive, or rarely in an autosomal dominant manner. In these cases, the condition is caused by genetic changes in the COL4A3 or COL4A4 genes. Diagnosis of the condition is based on family history of the condition, clinical signs, and specific testing such as a kidney biopsy. The diagnosis can be confirmed by genetic testing.
For a complete picture of Alport Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
